After finishing at $14.08 in the prior trading day, AbCellera Biologics Inc. (NASDAQ: ABCL) closed at $14.16, up 0.57%. In other words, the price has increased by $+0.08 from its previous closing price. On the day, 1377819 shares were traded. ABCL stock price reached its highest trading level at $14.42 during the session, while it also had its lowest trading level at $14.01.
Our goal is to gain a better understanding of ABCL by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.88. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on November 16, 2022, initiated with a Buy rating and assigned the stock a target price of $29.
On December 21, 2021, The Benchmark Company started tracking the stock assigning a Buy rating and target price of $27.
On November 19, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $33.Piper Sandler initiated its Overweight rating on November 19, 2021, with a $33 target price.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 when Thermopylae Holdings Ltd. bought 200,000 shares for $11.46 per share. The transaction valued at 2,292,460 led to the insider holds 55,844,391 shares of the business.
Thermopylae Holdings Ltd. bought 9,173 shares of ABCL for $73,842 on Jun 14. The 10% Owner now owns 55,644,391 shares after completing the transaction at $8.05 per share. On Jun 13, another insider, Thermopylae Holdings Ltd., who serves as the 10% Owner of the company, bought 54,915 shares for $8.03 each. As a result, the insider paid 441,066 and bolstered with 55,635,218 shares of the company.
As of this moment, AbCellera’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.77. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.68 while its Price-to-Book (P/B) ratio in mrq is 3.23.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $15.90, while it has fallen to a 52-week low of $5.42. The 50-Day Moving Average of the stock is 11.20, while the 200-Day Moving Average is calculated to be 9.94.
The stock has traded on average 1.80M shares per day over the past 3-months and 2.56M shares per day over the last 10 days, according to various share statistics. A total of 285.32M shares are outstanding, with a floating share count of 203.83M. Insiders hold about 19.60% of the company’s shares, while institutions hold 46.90% stake in the company. Shares short for ABCL as of Oct 13, 2022 were 19.53M with a Short Ratio of 18.23M, compared to 21.62M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.85% and a Short% of Float of 12.84%.
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0.18 and a low estimate of -$0.1, while EPS last year was -$0.08. The consensus estimate for the next quarter is $0, with high estimates of $0.29 and low estimates of -$0.11.
Analysts are recommending an EPS of between $1.04 and $0.32 for the fiscal current year, implying an average EPS of $0.53. EPS for the following year is -$0.32, with 6 analysts recommending between $0.36 and -$0.69.
A total of 7 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $633.7M, while the lowest revenue estimate was $412.67M, resulting in an average revenue estimate of $476.92M. In the same quarter a year ago, actual revenue was $375.2M, up 27.10% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $164.88M in the next fiscal year. The high estimate is $356.9M and the low estimate is $86.74M. The average revenue growth estimate for next year is down -65.40% from the average revenue estimate for this year.